AURKB and lung adenocarcinoma: Through analysis of the genome-wide mRNAs, microRNAs (miRNAs) and methylation profiles from LUAD project in The Cancer Genomics Atlas (TCGA) and the web-based bio-tool Lung Cancer Explorer (LCE) [15], we showed evidence for the use of AURKB as a prognosis biomarker in LUAD patients, and demonstrated potential genomic and epigenomic mechanisms associated with AURKB expression, explaining how AURKB accelerated the lung adenocarcinoma progression and limited patients’ survival.